Cytokinetics Inc (NASDAQ: CYTK) kicked off on Monday, down -4.22% from the previous trading day, before settling in for the closing price of $50.26. Over the past 52 weeks, CYTK has traded in a range of $40.53-$81.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 19.05% over the past five years. While this was happening, its average annual earnings per share was recorded 4.86%. With a float of $114.98 million, this company’s outstanding shares have now reached $117.89 million.
Let’s look at the performance matrix of the company that is accounted for 423 employees. In terms of profitability, gross margin is -2872.48%, operating margin of -16297.79%, and the pretax margin is -17906.24%.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 2.57%, while institutional ownership is 110.26%. The most recent insider transaction that took place on Feb 18 ’25, was worth 91,960. In this transaction EVP Research & Development of this company sold 2,000 shares at a rate of $45.98, taking the stock ownership to the 116,071 shares. Before that another transaction happened on Feb 04 ’25, when Company’s EVP Research & Development sold 2,000 for $48.06, making the entire transaction worth $96,120. This insider now owns 116,071 shares in total.
Cytokinetics Inc (CYTK) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.58% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 9.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1764.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.39, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -5.32 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ: CYTK) saw its 5-day average volume 1.98 million, a positive change from its year-to-date volume of 1.6 million. As of the previous 9 days, the stock’s Stochastic %D was 84.07%. Additionally, its Average True Range was 2.65.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 40.35%, which indicates a significant decrease from 67.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.97% in the past 14 days, which was higher than the 47.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $47.56, while its 200-day Moving Average is $52.85. Nevertheless, the first resistance level for the watch stands at $50.05 in the near term. At $51.95, the stock is likely to face the second major resistance level. The third major resistance level sits at $52.93. If the price goes on to break the first support level at $47.17, it is likely to go to the next support level at $46.19. The third support level lies at $44.29 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 5.68 billion has total of 118,014K Shares Outstanding. Its annual sales at the moment are 7,530 K in contrast with the sum of -526,240 K annual income. Company’s last quarter sales were recorded 460 K and last quarter income was -160,550 K.
